Covid vaccine safety risks

504 bookmarks
Newest
Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?
Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?
CanSino Biologics, Johnson & Johnson, and the University of Oxford are all using genetically engineered common cold viruses to make COVID-19 vaccines. The technology is more than 30 years in the making, but it’s yet to yield an effective vaccine for humans
·cen.acs.org·
Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?
Israel: Highest infection rate in the world
Israel: Highest infection rate in the world
Israel is reporting the highest coronavirus infection rate in the world, showing that neither vaccine mandates nor “vaccine passports” are suitable means to limit or end the pandemic.
·swprs.org·
Israel: Highest infection rate in the world
Covid-19 policy: Leading Israeli immunologist writes open letter: "It is time to admit failure"
Covid-19 policy: Leading Israeli immunologist writes open letter: "It is time to admit failure"
Professor Ehud Qimron, head of the Department of Microbiology and Immunology at Tel Aviv University and one of the leading Israeli immunologists, has written an open letter sharply criticizing the Israeli - and indeed global - management of the coronavirus pandemic.
·riotimesonline.com·
Covid-19 policy: Leading Israeli immunologist writes open letter: "It is time to admit failure"
Italy halts AstraZeneca vaccine for under-60s
Italy halts AstraZeneca vaccine for under-60s
The Italian government said on Friday it was restricting the use of the AstraZeneca COVID-19 vaccine to people over the age of 60, after a teenager who had received the shot died from a rare form of blood clotting.
·reuters.com·
Italy halts AstraZeneca vaccine for under-60s
First case of postmortem study in a patient vaccinated against SARS-CoV-2
First case of postmortem study in a patient vaccinated against SARS-CoV-2
We report on an 86-year-old male resident of a retirement home who received vaccine against SARS-CoV-2. Past medical history included systemic arterial hypertension, chronic venous insufficiency, dementia and prostate carcinoma. On January 9, 2021, the man received lipid nanoparticle-formulated, nucleoside-modified RNA vaccine BNT162b2 in a 30 μg dose. On that day and in the following 2 weeks, he presented with no clinical symptoms (Table 1). On day 18, he was admitted to hospital for worsening diarrhea.
·ijidonline.com·
First case of postmortem study in a patient vaccinated against SARS-CoV-2